ATE535543T1 - Aus dem neurotensin-rezeptor 3 entwickeltes peptid und seine verwendung bei der behandlung psychischer krankheiten - Google Patents

Aus dem neurotensin-rezeptor 3 entwickeltes peptid und seine verwendung bei der behandlung psychischer krankheiten

Info

Publication number
ATE535543T1
ATE535543T1 AT08872504T AT08872504T ATE535543T1 AT E535543 T1 ATE535543 T1 AT E535543T1 AT 08872504 T AT08872504 T AT 08872504T AT 08872504 T AT08872504 T AT 08872504T AT E535543 T1 ATE535543 T1 AT E535543T1
Authority
AT
Austria
Prior art keywords
neurotensin receptor
ntsr3
ligand
nucleic acid
peptide
Prior art date
Application number
AT08872504T
Other languages
English (en)
Inventor
Jean Mazella
Olivier Petrault
Marc Borsotto
Catherine Heurteaux
Catherine Widmann
Original Assignee
Centre Nat Rech Scient
Univ Nice Sophia Antipolis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Nice Sophia Antipolis filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE535543T1 publication Critical patent/ATE535543T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT08872504T 2007-12-21 2008-12-18 Aus dem neurotensin-rezeptor 3 entwickeltes peptid und seine verwendung bei der behandlung psychischer krankheiten ATE535543T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07291602A EP2077278A1 (de) 2007-12-21 2007-12-21 Peptid abgeleitet von Neurotensin-Rezeptor 3 und Anwendung zur Behandlung von psychiatrischen Erkrankungen
PCT/FR2008/001784 WO2009103898A1 (fr) 2007-12-21 2008-12-18 Peptide derive du recepteur 3 de la neurotensine et utilisation dans le traitement de maladies psychiatriques

Publications (1)

Publication Number Publication Date
ATE535543T1 true ATE535543T1 (de) 2011-12-15

Family

ID=39304741

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08872504T ATE535543T1 (de) 2007-12-21 2008-12-18 Aus dem neurotensin-rezeptor 3 entwickeltes peptid und seine verwendung bei der behandlung psychischer krankheiten

Country Status (7)

Country Link
US (1) US8252748B2 (de)
EP (2) EP2077278A1 (de)
JP (1) JP5487117B2 (de)
AT (1) ATE535543T1 (de)
CA (1) CA2709907C (de)
ES (1) ES2377489T3 (de)
WO (1) WO2009103898A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2077278A1 (de) 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptid abgeleitet von Neurotensin-Rezeptor 3 und Anwendung zur Behandlung von psychiatrischen Erkrankungen
JP6640725B2 (ja) * 2014-01-27 2020-02-05 セントレ ナショナル デ ラ レチャーチェ シャーティフィック ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
PT3380495T (pt) 2015-11-24 2021-08-19 Transfert Plus Sec Compostos peptídicos e conjugados peptídicos para o tratamento de cancro através de quimioterapia mediada por recetores
FR3057266B1 (fr) * 2016-10-11 2021-05-21 Centre Nat Rech Scient Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression
FR3057267A1 (fr) * 2016-10-11 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - Procede de diagnostic/determination de l'efficacite de traitement de la depression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1051485A1 (de) * 1998-01-27 2000-11-15 Smithkline Beecham Plc Trek-1 ähnliche zwei poren kaliumkanal
WO2004056385A2 (en) * 2002-12-20 2004-07-08 Neuronicon Aps Modulation of activity of neurotrophins
EP2077278A1 (de) * 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptid abgeleitet von Neurotensin-Rezeptor 3 und Anwendung zur Behandlung von psychiatrischen Erkrankungen

Also Published As

Publication number Publication date
EP2077278A1 (de) 2009-07-08
EP2229408A1 (de) 2010-09-22
ES2377489T3 (es) 2012-03-28
WO2009103898A1 (fr) 2009-08-27
CA2709907A1 (fr) 2009-08-27
EP2229408B1 (de) 2011-11-30
US20110237515A1 (en) 2011-09-29
CA2709907C (fr) 2016-11-08
JP5487117B2 (ja) 2014-05-07
US8252748B2 (en) 2012-08-28
JP2011505864A (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
TWI666026B (zh) Ｗｔ１抗原胜肽結合疫苗
ATE535543T1 (de) Aus dem neurotensin-rezeptor 3 entwickeltes peptid und seine verwendung bei der behandlung psychischer krankheiten
WO2019023651A2 (en) MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR
AU2014227712B2 (en) Peptide compositions
CA2390349A1 (en) Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
CU20120116A7 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5
Steel et al. Perfluoroarene-based peptide macrocycles that inhibit the Nrf2/Keap1 interaction
CN102131775A (zh) 雄激素受体n-末端活化的小分子抑制剂
Misawa et al. Structural development of stapled short helical peptides as vitamin D receptor (VDR)–coactivator interaction inhibitors
Carotenuto et al. Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor
Shimamura et al. Identification of a stable chemerin analog with potent activity toward ChemR23
Fotsch et al. Design of a new peptidomimetic agonist for the melanocortin receptors based on the solution structure of the peptide ligand, Ac-Nle-cyclo [Asp-Pro-dPhe-Arg-Trp-Lys]-NH2
Gonçalves et al. From identification to functional characterization of cyriotoxin‐1a, an antinociceptive toxin from the spider Cyriopagopus schioedtei
Takeuchi et al. The selectivity of 6-nor-ABA and 7′-nor-ABA for abscisic acid receptor subtypes
KR20230057350A (ko) 스테이플화된 펩티드 및 이의 방법
Zhao et al. The conventional turns rather than irregular γ-/β-turn secondary structures accounting for the antitumor activities of cyclic peptide Phakellistatin 6 analogs
CN107602670B (zh) 一种可拮抗ewsr1蛋白rna结合活性的多肽eip-22及其应用
DK1931792T3 (da) Transgene aloeplanter til produktion af proteiner og beslægtede fremgangsmåder
Chingle et al. Azopeptides: Synthesis and pericyclic chemistry
Li et al. BarH1 regulates odorant-binding proteins expression and olfactory perception of Monochamus alternatus Hope
Zhang et al. TFAP2C exacerbates psoriasis-like inflammation by promoting Th17 and Th1 cells activation through regulating TEAD4 transcription
Zhou et al. Progress in the participation of Ca2+–calmodulin in heat shock signal transduction
Jiang et al. Interleukin-10 inhibits angiotensin II-induced decrease in neuronal potassium current
Okada et al. Structure–activity relationship studies on quorum sensing ComXRO-E-2 pheromone